- Business Wire•19 minutes agoUpdated KEYTRUDA® (pembrolizumab) Findings in Patients with Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma Presented at 58th Annual Meeting of the American Society of Hematology
Merck , known as MSD outside the United States and Canada, announced today study findings demonstrating that KEYTRUDA® , the company’s anti-PD-1 therapy, achieved an overall response rate of 41 percent with follow-up of up to 27 months in patients with relapsed or refractory primary mediastinal large B-cell lymphoma , a type of non-Hodgkin lymphoma, who were ineligible for or failed to respond to autologous ...
- Zacks•41 minutes ago
Kite Pharma, Inc. (KITE) announced it has initiated a rolling submission of the Biologic License Application (BLA) for its lead pipeline candidate, KTE-C19, to the FDA.
Frazier took the stage at Forbes Healthcare Summit in New York to discuss the changing landscape of cancer treatment with fellow heavy hitters and shared his thoughts on everything from cost vs. value to how one drug breakthrough leads to others.
MRK : Summary for Merck & Company, Inc. Common St - Yahoo Finance
Merck & Co., Inc. (MRK)
NYSE - NYSE Real Time Price. Currency in USD
Add to watchlist
|Bid||61.00 x 300|
|Ask||61.01 x 200|
|Day's Range||60.67 - 61.52|
|52 Week Range||47.97 - 65.46|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||31.11|
|Dividend & Yield||1.88 (3.08%)|
|1y Target Est||N/A|